Anthem Biosciences Ltd: India's Premier CRDMO Play Unlocking Biologics Potential

Anthem Biosciences Ltd (NSE: ANTHEM | BSE: 544449) — Equity Research Report | June 2026

Company Overview

Anthem Biosciences Ltd (ABL) is one of India's leading Contract Research, Development, and Manufacturing Organizations (CRDMOs), offering fully integrated services across the drug discovery, development, and manufacturing value chain. Incorporated in 2006, the company is headquartered in Bengaluru, Karnataka, and has carved a niche for itself in the high-growth outsourcing segment of the global pharmaceutical industry.

What distinguishes Anthem from most Indian CRDMO peers is its dual capability in both New Chemical Entity (NCE) and New Biological Entity (NBE) programs. The company has built proprietary technology platforms spanning RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides — placing it squarely in the sweet spot of the global biologics boom. As of June 1, 2026, Anthem trades at ₹742 per share, commanding a market capitalization of ₹41,812 crore, reflecting the market's premium valuation for high-technology CDMO businesses with strong growth runways.

Business Model and Revenue Streams

Anthem operates through two primary business verticals:

1. CRDMO Services (Core Business)

The CRDMO segment is the company's bread and butter, contributing the bulk of its revenues. This segment encompasses:

• Contract Research: Early-stage discovery chemistry, medicinal chemistry, and process research for global pharma and biotech clients.
• Contract Development: Process development, scale-up, analytical method development, and regulatory filing support.
• Contract Manufacturing: Commercial manufacturing of active pharmaceutical ingredients (APIs), intermediates, and specialty molecules under cGMP conditions.

Anthem's CRDMO model is built on long-term partnerships with global pharmaceutical companies. The company serves clients across North America, Europe, and Asia-Pacific, with a diversified customer base spanning large pharma, mid-size biotech, and virtual pharma companies.

2. Specialty Ingredients

The company also manufactures and sells specialty ingredients including enzymes, probiotics, and other bio-based ingredients for the nutraceutical, food, and animal nutrition industries. This vertical provides revenue diversification and leverages the company's fermentation and bioprocessing capabilities.

Key Financial Metrics (As of June 2026)

The stock is currently trading at a ~20% discount to its 52-week high of ₹874, having corrected from peaks amid broader market volatility. At 68.6x trailing P/E, the stock commands a significant premium to the broader market, reflecting the market's pricing of its high-growth, high-margin business model.

Quarterly Financial Performance (FY2025-26)

Anthem reported accelerating revenue and profit growth through FY2026, with particularly strong momentum in the second half:

Key Quarterly Observations:

• Q4 FY26 (Mar 2026) was the strongest quarter with revenue of ₹611 crore and net profit of ₹190 crore, delivering a record OPM of 44%.
• Net profit growth YoY was exceptional — Q4 FY26 profit of ₹190 crore versus Q4 FY25's ₹83 crore, representing ~129% YoY growth.
• Revenue growth YoY in Q4 was also robust at ₹611 crore versus ₹483 crore in Q4 FY25, a jump of ~26.5%.
• The operating profit margin expanded significantly from 40% in Q4 FY25 to 44% in Q4 FY26, indicating improving operating leverage and a richer business mix.
• The December 2025 quarter was a seasonal trough with lower revenue of ₹423 crore and profit of ₹93 crore, but the March quarter snap-back was impressive.
• Other income has been volatile, ranging from ₹8 crore to ₹52 crore across quarters, reflecting treasury gains and investment income fluctuations.

Annual Financial Performance (FY2020–FY2026)

Profit & Loss Summary

Note: EPS figures changed post-IPO due to significant equity dilution. Pre-IPO EPS (FY2020-FY2022) reflects a much smaller share base.

Growth Metrics

Key Annual Observations:

• Revenue has grown nearly 3.4x from ₹633 crore in FY2020 to ₹2,124 crore in FY2026, reflecting the company's rapid scaling.
• Net profit grew from ₹93 crore to ₹592 crore over the same period, a 6.4x increase, demonstrating strong operating leverage.
• Operating margins have been resilient in the 29-46% range, with the peak in FY2022 (46%) and a healthy 39% in FY2026.
• Depreciation has nearly doubled from ₹62 crore to ₹134 crore, reflecting heavy capex in fixed assets for capacity expansion.
• Interest costs have declined from ₹20 crore to ₹7 crore, signaling the company's deleveraging journey.
• Other income surged to ₹131 crore in FY2026 (from ₹85 crore in FY2025), likely from treasury gains on IPO proceeds and investments.
• The dividend payout has been 0% across all years, consistent with a growth-oriented reinvestment strategy.

Balance Sheet Strength

Balance Sheet Summary

Balance Sheet Analysis:

• Total assets have expanded 4.4x from ₹787 crore in FY2020 to ₹3,429 crore in FY2026, driven by massive capacity expansion.
• Fixed assets grew from ₹306 crore to ₹783 crore, while CWIP (Capital Work in Progress) peaked at ₹345 crore in FY2024 before moderating to ₹264 crore in FY2026, suggesting major capex cycles are nearing completion.
• Borrowings have been dramatically reduced from ₹159 crore to just ₹53 crore, confirming the company is almost debt-free — a key strength noted by Screener.in.
• The debt-to-equity ratio stands at a negligible ~0.02x (₹53 crore borrowings vs ₹3,042 crore net worth), making Anthem one of the least leveraged companies in its peer group.
• Reserves have surged from ₹413 crore to ₹2,930 crore, a 7x increase, driven by IPO proceeds and retained earnings.
• Investments jumped sharply to ₹1,007 crore in FY2026 (from ₹433 crore), indicating deployment of IPO proceeds into financial investments.

Cash Flow Analysis

Cash Flow Highlights:

• FY2026 was a landmark year for cash generation — operating cash flow surged to ₹844 crore, the highest ever, and free cash flow hit ₹637 crore.
• The CFO-to-Operating Profit ratio of 126% in FY2026 is exceptional, meaning the company collected cash faster than it booked accounting profits — a sign of high-quality earnings.
• FY2024 was a cash flow trough with negative FCF of -₹156 crore and CFO of just ₹140 crore (CFO/OP of 51%), likely due to working capital absorption from rapid growth.
• Cumulative free cash flow over 7 years (FY2020-FY2026) stands at approximately ₹1,312 crore, demonstrating the business's strong cash-generating ability.
• Investing outflows of ₹702 crore in FY2026 reflect continued capex deployment and investment activity funded by robust internal accruals.
• Financing outflows have moderated to -₹40 crore, indicating minimal net debt movement and no significant equity dilution post-IPO.

Operating Efficiency Ratios

Efficiency Observations:

• Inventory days collapsed from 167 days in FY2025 to just 56 days in FY2026, a remarkable improvement indicating better inventory management or a shift in product mix.
• Cash conversion cycle improved sharply from 202 days to 124 days, reflecting faster working capital turnover.
• Debtor days of 101 days are reasonable for a CRDMO business serving global clients with standard payment terms.
• Working capital days of 207 days in FY2026 remain elevated, suggesting the business requires significant working capital — but the improving trend is positive.
• ROCE has recovered from 24% in FY2024 to 30% in FY2026, demonstrating improving capital efficiency as new capacity gets utilized.

Shareholding Pattern

The shareholding pattern reveals a tightly held promoter-driven company with growing institutional interest:

Shareholding Analysis:

• Promoter holding is rock-solid at 74.67%, indicating strong promoter commitment and alignment with minority shareholders.
• DII holding has surged from 7.21% to 11.55% in just two quarters, a ~60% increase that signals growing conviction from domestic institutional investors (mutual funds, insurance companies).
• FII holding is relatively low at 1.28% and has been declining from 1.66%, suggesting foreign investors may find the valuation stretched or are yet to discover this mid-cap CDMO story.
• Retail/public holding has dropped from 16.42% to 12.48%, with the number of shareholders declining from 2,17,681 to 1,80,220 — indicating consolidation of shares into stronger hands (institutions).
• The low FII holding presents a potential upside catalyst — as the company continues to deliver strong quarterly results, increased FII participation could provide valuation support.

Peer Comparison

Anthem is the largest company by market capitalization in its listed biotechnology CDMO peer group:

Peer Analysis:

• Anthem's market cap of ₹41,812 crore is ~10x larger than the next biggest peer (Advanced Enzyme at ₹4,182 crore), demonstrating its dominance in the Indian CRDMO/biotech listed space.
• The Q4 profit growth of 128.88% vastly outperforms peers, with Advanced Enzyme growing at 61.91% and most others reporting losses.
• Anthem's ROCE of 30.45% is more than 2x that of Advanced Enzyme (13.89%), confirming superior capital efficiency.
• At 68.65x P/E, Anthem commands a significant premium over Advanced Enzyme's 26.04x, reflecting the market's preference for Anthem's higher growth, superior margins, and larger scale.
• Among the six listed peers, four are loss-making (CCME Global, Vivo Bio Tech at NP level, Shree Ganesh Bio, Genomic Valley), making Anthem the standout profitable player in this niche.

Index Membership

Anthem is a constituent of several important indices, which provides passive fund flow support:

• BSE Healthcare
• Nifty 500
• BSE IPO
• Nifty LargeMidcap 250
• Nifty Midcap 150

Membership in the Nifty Midcap 150 and Nifty LargeMidcap 250 ensures periodic buying from index funds and ETFs tracking these benchmarks, providing a structural demand floor for the stock.

Industry Context: India's CRDMO Opportunity

The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) market sits at the intersection of several powerful global megatrends. India's pharmaceutical outsourcing industry has evolved dramatically from being a low-cost generics manufacturing hub to a provider of sophisticated end-to-end drug development and manufacturing services. This evolution mirrors the broader shift in the global pharmaceutical industry toward asset-light models and external partnerships.

Market Size and Growth

The global CRDMO market is estimated at approximately $150-180 billion as of 2025-26, with India's share growing at a faster clip than the global average. India's CRDMO industry is projected to reach $25-30 billion by 2030, up from approximately $12-15 billion in 2024, representing a CAGR of 12-15%. Several structural factors underpin this growth trajectory:

• Patent cliff dynamics: As blockbuster drugs lose patent protection, originator companies increasingly outsource manufacturing to CDMOs to reduce costs while simultaneously investing in next-generation molecules that require specialized capabilities.

• Biologics revolution: The shift from small-molecule drugs to biologics (monoclonal antibodies, ADCs, cell therapies, gene therapies) requires highly specialized manufacturing infrastructure that most pharma companies prefer to outsource.

• Regulatory complexity: Increasing regulatory requirements globally (especially from the US FDA and EMA) have raised the bar for manufacturing quality, favoring established CDMOs with proven compliance track records over in-house manufacturing.

• Speed to market: In a competitive pharmaceutical landscape, the ability to rapidly develop and manufacture drugs is a critical differentiator. CDMOs with integrated capabilities can compress development timelines significantly.

India's Competitive Advantages

Indian CRDMO companies enjoy several structural advantages over global peers:

1. Cost arbitrage: Manufacturing costs in India are typically 30-50% lower than in the US and Europe, while quality standards remain comparable.

2. Deep scientific talent pool: India produces over 500,000 engineering graduates and 200,000 science graduates annually, providing a vast talent pool for R&D-intensive CRDMO operations.

3. Regulatory track record: Indian CRDMO facilities have an excellent compliance record with major global regulatory agencies, including the US FDA, EMA, PMDA (Japan), and TGA (Australia).

4. English language advantage: The ability to communicate seamlessly with Western clients in English provides a significant operational advantage in client relationship management.

5. Government support: The Indian government's Production Linked Incentive (PLI) scheme for pharmaceuticals, with an outlay of approximately ₹15,000 crore, provides additional tailwinds for domestic CRDMO expansion.

Anthem Biosciences is well-positioned to capitalize on these industry dynamics given its integrated service offerings, advanced technology platforms, and strong regulatory compliance history.

Management and Promoter Background

Anthem Biosciences was founded by a team of experienced pharmaceutical and biotechnology professionals. The company's founders bring decades of experience in drug discovery, process chemistry, and bioprocess engineering. The management team has successfully steered the company from a startup in 2006 to a ₹41,812 crore market cap enterprise in just two decades — a remarkable achievement in India's pharmaceutical landscape.

The promoter holding of 74.67% as of March 2026 signals unwavering commitment from the founding team. Notably, promoters have not diluted their holdings significantly even after the IPO, choosing to retain a dominant stake. This is a positive signal for minority shareholders, as it indicates the promoters' confidence in the long-term value creation potential of the business.

The company's headquarters and primary manufacturing facility are located in Bengaluru, India's biotechnology capital. Bengaluru's ecosystem of research institutions, biotech startups, and multinational pharma companies provides Anthem with access to talent, collaborators, and clients.

Capacity Expansion and Capital Expenditure

A defining feature of Anthem's growth story over the past few years has been its aggressive capacity expansion program. The balance sheet data reveals the scale of investment:

• Fixed assets grew from ₹306 crore in FY2020 to ₹783 crore in FY2026, a 2.6x increase.
• CWIP peaked at ₹345 crore in FY2024 before declining to ₹264 crore in FY2026, suggesting that the largest capex projects are either completed or nearing completion.
• Total capex (fixed assets + CWIP change) over FY2020-FY2026 amounts to approximately ₹691 crore (change in fixed assets plus change in CWIP), funded primarily through internal accruals and IPO proceeds.

This heavy investment in manufacturing capacity is now translating into revenue growth and operating leverage, as evidenced by the 44% OPM in Q4 FY2026 — the highest quarterly margin in recent history. As utilization rates improve on the newly commissioned capacity, margins should continue to expand, and the return on incremental invested capital should improve.

The company's investments portfolio surged to ₹1,007 crore in FY2026 (from ₹433 crore in FY2025), indicating that a portion of IPO proceeds has been deployed into financial investments. While this provides additional income (other income of ₹131 crore in FY2026), investors should monitor whether these investments are eventually deployed into value-accretive growth projects.

Investment Thesis: Why Anthem Biosciences?

1. Structural Tailwinds in Global CRDMO Outsourcing

The global pharmaceutical CRDMO market is projected to grow at 8-12% CAGR through 2030, driven by:

• Increasing outsourcing by pharma companies seeking to reduce fixed costs and accelerate drug development timelines.
• Complexity of new modalities (biologics, ADCs, oligonucleotides, cell & gene therapy) that require specialized capabilities most pharma companies lack in-house.
• China+1 diversification — global clients are actively diversifying their supply chains away from China, creating a significant opportunity for Indian CRDMOs.

2. Differentiated Technology Platform

Anthem's capabilities in RNAi, ADCs, peptides, lipids, and oligonucleotides place it in the highest-growth segments of the biologics value chain. These are complex, high-barrier-to-entry technologies that command premium pricing and create deep customer stickiness.

3. Operating Leverage Play

With CWIP moderating from ₹345 crore to ₹264 crore, the heavy capex cycle appears to be winding down. As new capacity comes online and utilization improves, the company should benefit from significant operating leverage — as evidenced by the 44% OPM in Q4 FY2026 versus the 36% annual average.

4. De-risked Balance Sheet

With borrowings of just ₹53 crore and a debt-to-equity ratio of ~0.02x, Anthem has the financial flexibility to:

• Fund future capex through internal accruals (FY2026 FCF of ₹637 crore).
• Pursue acquisitions in adjacent technology areas.
• Weather any cyclical downturns in client spending.

5. Strong Promoter Backing

At 74.67%, promoter skin in the game is among the highest in the Indian mid-cap pharma/CDMO space. The increasing DII holding (11.55%) further validates the institutional quality of the story.

Risk Factors

1. Premium Valuation Risk

At 68.6x P/E and ~14x book value, the stock is priced for perfection. Any slowdown in revenue growth or margin contraction could trigger a significant de-rating. The stock is already ~20% below its 52-week high of ₹874.

2. Client Concentration Risk

As a CRDMO, Anthem's revenues are inherently dependent on a relatively small number of large client programs. Loss of a key client or discontinuation of a major program could disproportionately impact financials.

3. Regulatory and Quality Risk

Pharmaceutical manufacturing is subject to stringent regulatory oversight (US FDA, EMA, etc.). Any adverse inspection findings or regulatory actions could disrupt operations and damage reputation.

4. Working Capital Intensity

With working capital days of 207 and cash conversion cycle of 124 days, the business requires significant capital tied up in operations. Rapid growth could strain cash flows if working capital management deteriorates.

5. Competitive Threats

The Indian CRDMO space is getting increasingly competitive with players like Syngene International, Divi's Laboratories, Piramal Pharma, and Laurus Labs all expanding their CDMO capabilities. Global players like Samsung Biologics and Lonza also compete for large mandates.

6. Foreign Exchange Risk

With a significant portion of revenues from international clients, the company is exposed to INR/USD and INR/EUR fluctuations. A strengthening rupee could impact reported revenues and margins.

Technical View

The stock is currently trading at ₹742, down 2.33% on the session (as of June 1, 2026, 1:16 PM). The 52-week range of ₹579–₹874 provides context — the stock is trading closer to the middle of its range, suggesting a period of consolidation after the post-IPO rally.

Key technical levels to watch:

• Support: ₹700 (psychological level), ₹650 (near 52-week low zone)
• Resistance: ₹800 (round number), ₹874 (52-week high)
• Trend: Neutral to mildly bearish given the current price is below the midpoint of the 52-week range

Valuation Summary

At 68.6x trailing P/E, Anthem is not cheap. However, the valuation is supported by:

• 35% TTM profit growth (delivering a PEG of ~2x)
• 30%+ ROCE with improving trajectory
• Near-zero debt and strong FCF generation
• Structural growth tailwinds in the CRDMO outsourcing market

For long-term investors, the key question is whether Anthem can sustain 25-30%+ earnings growth over the next 3-5 years. If it does, the current valuation will look reasonable in hindsight.

Conclusion

Anthem Biosciences represents one of India's most compelling high-growth CRDMO stories, combining differentiated technology capabilities, strong financial execution, and a clean balance sheet. The company has demonstrated its ability to scale revenues 3.4x in 6 years while maintaining 30%+ ROCE and generating cumulative free cash flow of ₹1,300+ crore.

The Q4 FY2026 results — with revenue of ₹611 crore, OPM of 44%, and net profit of ₹190 crore — suggest the company is entering a phase of accelerating growth and improving profitability. The 129% YoY profit growth in the latest quarter and the surge in DII holdings from 7.21% to 11.55% are strong validation signals.

However, investors should be mindful of the premium valuation (68.6x P/E) and concentrated promoter holding (74.67%). The stock is best suited for investors with a 3-5 year investment horizon who are comfortable paying up for quality and growth in the rapidly expanding global CRDMO market.

At the current price of ₹742, Anthem offers a compelling risk-reward for patient investors who believe in the structural growth story of Indian CRDMOs, with the stock trading ~20% below its 52-week high and poised to benefit from capacity utilization ramp-up, operating leverage, and potential FII interest.